Zhitong Finance App News, Baike Biotech (688276.SH) issued an announcement. The company recently received the “Notice of Acceptance” of the clinical trial application for a recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (“RSV antibody”) issued by the State Drug Administration.

The RSV antibody accepted by the company is used to prevent lower respiratory tract infections caused by RSV in newborns and infants. Pre-clinical pharmacodynamics studies have shown that the product has good efficacy; preclinical toxicology studies have shown that the product is generally well tolerated, safe and controllable; the product can cover a complete RSV epidemic season with a single dose, improving drug compliance and prevention convenience.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.